Colorectal cancer is one of the more commonly diagnosed cancers among both men and women today. Despite the fact that it most exclusively affects older persons, colorectal cancer is continuing to be diagnosed in younger and younger patients. CURE Connections wants to answer any questions you might have when it comes to managing colorectal cancer. This program includes information as shared by an expert physician, and personal accounts from patients and their caretakers who have dealt with colorectal cancer.
Keytruda bested chemotherapy, delaying disease progression or death by 40%, in a clinical trial that led to the drug’s approval for use as a single initial treatment for patients with colorectal cancer.
While follow-up data on the BEACON CRC study demonstrated superior overall survival for certain patients with metastatic colorectal cancer receiving Braftovi, Mektovi and Erbitux, an exploratory analysis is needed to understand if this treatment can impact a wider subset of patients.
“These long-awaited trial results will change clinical practice,” lead study author Dr. Thierry André, of the Sorbonne Université and Hôpital Saint Antoine in Paris, said in an ASCO-issued press release.
The Braftovi-Erbitux combination will become the preferred second-line treatment option in treatment of adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, according to one expert.